PYC Therapeutics Limited

Compare

38 Followers

PYC Stock Chart & Stats

AU$1.20

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$1.20

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.85 - AU$2.03

Previous CloseN/A

Volume307.79K

Average Volume (3M)1.07M

Market Cap

AU$699.91M

Enterprise ValueAU$549.20M

Total Cash (Recent Filing)AU$153.05M

Total Debt (Recent Filing)AU$1.02M

Price to Earnings (P/E)―

Beta1.60

Next Earnings

Feb 26, 2026

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding583,260,440

10 Day Avg. Volume498,552

30 Day Avg. Volume1,072,815

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)3.84

Price to Sales (P/S)27.69

P/FCF Ratio-12.39

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$2.58

Price Target Upside115.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsPYC-003 is now being assessed in a Phase I in healthy volunteers, entering a catalyst-rich period across all of its clinical programs.

Market ValidationNVS Acquisition of RGLS Further Validates MOA for Potentially Best-in-Class PYC-003.

ValuationThe upfront payment of US$7.00 per share infers an EV of US$0.8B – if applied to PYC’s capital structure, this generates a PYC valuation of AU$2.35 per share (US$1.50).

Bears Say

Competition And Market DynamicsAnalyst's recommendation is based on discounted, risk-adjusted multiples of 5 year forecast sales of the company’s three clinical candidates.

Probability Of SuccessApplying a 15% probability to the CVR, increases the valuation to AU$2.70 (US$1.72).

Speculative RiskBloom Burton is initiating research coverage of genetic medicine company, PYC Therapeutics, with a BUY rating (Speculative risk).

PYC Therapeutics Limited News

PYC Therapeutics Advances Study on Genetic Eye Disorder Treatment

PYC Therapeutics Limited (($AU:PYC)) announced an update on their ongoing clinical study. PYC Therapeutics Limited is conducting a...

3d ago

PYC

PYC Therapeutics Advances in ADPKD Treatment with PYC-003 Study

PYC Therapeutics Limited (($AU:PYC)) announced an update on their ongoing clinical study. PYC Therapeutics Limited is conducting a...

3d ago

PYC

PYC Therapeutics Advances in Genetic Eye Disorder Treatment with PYC-001 Study

PYC Therapeutics Limited (($AU:PYC)) announced an update on their ongoing clinical study. Study Overview: PYC Therapeutics Limited is...

3d ago

PYC

PYC Therapeutics’ VP-001 Study: A Promising Step in Retinal Dystrophy Treatment

PYC Therapeutics Limited (($AU:PYC)) announced an update on their ongoing clinical study. Study Overview: PYC Therapeutics is conducting...

3d ago

PYC

PYC Therapeutics Advances Retinal Dystrophy Study with VP-001

PYC Therapeutics Limited (($AU:PYC)) announced an update on their ongoing clinical study. PYC Therapeutics Limited is conducting a...

3d ago

PYC

PYC Therapeutics Advances Precision Medicine Pipeline in Q3 2025

An update from PYC Therapeutics Limited ( ($AU:PYC) ) is now available. PYC Therapeutics Limited announced significant progress...

4d ago

PYC

PYC Therapeutics Launches Global Trial for ADOA Treatment

PYC Therapeutics Limited ( ($AU:PYC) ) has issued an update. PYC Therapeutics Limited has initiated a global Phase...

10d ago

PYC

PYC Therapeutics Announces 2025 Annual General Meeting

PYC Therapeutics Limited ( ($AU:PYC) ) has provided an announcement. PYC Therapeutics Limited has announced its Annual General...

14d ago

PYC

PYC Therapeutics Updates Stakeholders on Business Progress

PYC Therapeutics Limited ( ($AU:PYC) ) has shared an announcement. PYC Therapeutics Limited has released a presentation providing...

18d ago

PYC

PYC Therapeutics to Host Investor Webinar on Strategic Developments

PYC Therapeutics Limited ( ($AU:PYC) ) has issued an announcement. PYC Therapeutics Limited announced an upcoming investor webinar...

1M ago

PYC

PYC FAQ

What was PYC Therapeutics Limited’s price range in the past 12 months?

PYC Therapeutics Limited lowest share price was AU$0.85 and its highest was AU$2.03 in the past 12 months.

What is PYC Therapeutics Limited’s market cap?

PYC Therapeutics Limited’s market cap is AU$699.91M.

When is PYC Therapeutics Limited’s upcoming earnings report date?

PYC Therapeutics Limited’s upcoming earnings report date is Feb 26, 2026 which is in 119 days.

How were PYC Therapeutics Limited’s earnings last quarter?

PYC Therapeutics Limited released its earnings results on Aug 28, 2025. The company reported -AU$0.046 earnings per share for the quarter, beating the consensus estimate of -AU$0.079 by AU$0.033.

Is PYC Therapeutics Limited overvalued?

According to Wall Street analysts PYC Therapeutics Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does PYC Therapeutics Limited pay dividends?

PYC Therapeutics Limited does not currently pay dividends.

What is PYC Therapeutics Limited’s EPS estimate?

PYC Therapeutics Limited’s EPS estimate is -0.07.

How many shares outstanding does PYC Therapeutics Limited have?

PYC Therapeutics Limited has 583,260,440 shares outstanding.

What happened to PYC Therapeutics Limited’s price movement after its last earnings report?

PYC Therapeutics Limited reported an EPS of -AU$0.046 in its last earnings report, beating expectations of -AU$0.079. Following the earnings report the stock price went down -0.769%.

Which hedge fund is a major shareholder of PYC Therapeutics Limited?

Currently, no hedge funds are holding shares in AU:PYC

PYC Therapeutics Limited Stock Smart Score

Underperform

Fundamentals

Return on Equity

-40.23%

Trailing 12-Months

Asset Growth

100.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

PYC Therapeutics Limited

PYC Therapeutics Limited (PYC) is a biotechnology company focused on developing innovative RNA-based therapeutics. The company specializes in next-generation RNA-targeted therapies aimed at treating genetic disorders and diseases, particularly those associated with the central nervous system. PYC leverages its proprietary technology platforms to design and deliver RNA therapeutics that can modify gene expression, offering potential treatments for conditions such as muscle dystrophies and other genetic disorders.

PYC Therapeutics Limited (PYC) Earnings & Revenues

Historic Earnings Reports

PYC Stock 12 Month Forecast

Average Price Target

AU$2.58

▲(115.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","2":"AU$2","3":"AU$3","-1":"-AU$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$2.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$2.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$2.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.1976923076923078,1.3353846153846154,1.4730769230769232,1.6107692307692307,1.7484615384615385,1.8861538461538463,2.023846153846154,2.161538461538462,2.2992307692307694,2.436923076923077,2.5746153846153845,2.7123076923076925,{"y":2.85,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.176923076923077,1.2938461538461539,1.4107692307692308,1.5276923076923077,1.6446153846153848,1.7615384615384615,1.8784615384615386,1.9953846153846153,2.1123076923076924,2.229230769230769,2.3461538461538463,2.4630769230769234,{"y":2.58,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.1553846153846155,1.2507692307692309,1.3461538461538463,1.4415384615384617,1.536923076923077,1.6323076923076922,1.7276923076923076,1.823076923076923,1.9184615384615384,2.0138461538461536,2.109230769230769,2.2046153846153844,{"y":2.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.04,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >